Rosa L de Jager1, Niek F Casteleijn2, Esther de Beus1, Michiel L Bots3, Evert-Jan E Vonken4, Ron T Gansevoort5, Peter J Blankestijn1. 1. Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands. 2. Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands. 5. Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
Background: Loin pain haematuria syndrome (LPHS) and autosomal dominant polycystic kidney disease (ADPKD) are the most important non-urological conditions to cause chronic severe kidney-related pain. Multidisciplinary programmes and surgical methods have shown inconsistent results with respect to pain reduction. Percutaneous catheter-based renal denervation (RDN) could be a less invasive treatment option for these patients. Methods: Our aim was to explore the change in perceived pain and use of analgesic medication from baseline to 3, 6 and 12 months after RDN. Patients with LPHS or ADPKD, who experienced kidney-related pain ≥3 months with a visual analogue scale (VAS) score ≥ 50/100 could be included. Percutaneous RDN was performed with a single-electrode radiofrequency ablation catheter. Results:RDN was performed in 11 patients (6 with LPHS and 5 with ADPKD). Perceived pain declined in the whole group by 23 mm (P = 0.012 for the total group). In patients with LPHS and ADPKD, the median daily defined dosage of analgesic medication decreased from 1.6 [interquartile range (IQR) 0.7-2.3] and 1.4 (IQR 0.0-7.4) at baseline to 0.3 (IQR 0.0-1.9; P = 0.138) and 0.0 (IQR 0.0-0.8; P = 0.285) at 12 months, respectively. Mean estimated glomerular filtration rate decreased in the whole group by 5.4 mL/min/1.73 m2 at 6 months compared with baseline (P = 0.163). Conclusions: These results suggest that percutaneous catheter-based RDN reduces pain complaints and the use of analgesic medication in patients with LPHS or ADPKD. The present results can serve as the rationale for a larger, preferably randomized (sham) controlled study.
RCT Entities:
Background: Loin pain haematuria syndrome (LPHS) and autosomal dominant polycystic kidney disease (ADPKD) are the most important non-urological conditions to cause chronic severe kidney-related pain. Multidisciplinary programmes and surgical methods have shown inconsistent results with respect to pain reduction. Percutaneous catheter-based renal denervation (RDN) could be a less invasive treatment option for these patients. Methods: Our aim was to explore the change in perceived pain and use of analgesic medication from baseline to 3, 6 and 12 months after RDN. Patients with LPHS or ADPKD, who experienced kidney-related pain ≥3 months with a visual analogue scale (VAS) score ≥ 50/100 could be included. Percutaneous RDN was performed with a single-electrode radiofrequency ablation catheter. Results: RDN was performed in 11 patients (6 with LPHS and 5 with ADPKD). Perceived pain declined in the whole group by 23 mm (P = 0.012 for the total group). In patients with LPHS and ADPKD, the median daily defined dosage of analgesic medication decreased from 1.6 [interquartile range (IQR) 0.7-2.3] and 1.4 (IQR 0.0-7.4) at baseline to 0.3 (IQR 0.0-1.9; P = 0.138) and 0.0 (IQR 0.0-0.8; P = 0.285) at 12 months, respectively. Mean estimated glomerular filtration rate decreased in the whole group by 5.4 mL/min/1.73 m2 at 6 months compared with baseline (P = 0.163). Conclusions: These results suggest that percutaneous catheter-based RDN reduces pain complaints and the use of analgesic medication in patients with LPHS or ADPKD. The present results can serve as the rationale for a larger, preferably randomized (sham) controlled study.
Authors: Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres Journal: Nat Rev Dis Primers Date: 2018-12-06 Impact factor: 52.329
Authors: Ivan Urits; Nathan Li; Amnon A Berger; Paul Walker; Brendan Wesp; Alec M Zamarripa; Daniel An; Elyse M Cornett; Alaa Abd-Elsayed; Alan D Kaye Journal: Curr Pain Headache Rep Date: 2021-01-25
Authors: Patrizia Natale; Ronald D Perrone; Allison Tong; Tess Harris; Elyssa Hannan; Angela Ju; Eva Burnette; Niek F Casteleijn; Arlene Chapman; Sarah Eastty; Ron T Gansevoort; Marie Hogan; Shigeo Horie; Bertrand Knebelmann; Richard Lee; Reem A Mustafa; Richard Sandford; Amanda Baumgart; Jonathan C Craig; Gopala K Rangan; Bénédicte Sautenet; Andrea K Viecelli; Noa Amir; Nicole Evangelidis; Chandana Guha; Charlotte Logeman; Karine Manera; Andrea Matus Gonzalez; Martin Howell; Giovanni F M Strippoli; Yeoungjee Cho Journal: Clin Kidney J Date: 2021-07-06
Authors: Sheran Li; Cara M Hildreth; Ahmed A Rahman; Sean A Barton; Benjamin F Wyse; Chai K Lim; Paul M Pilowsky; Jacqueline K Phillips Journal: Sci Rep Date: 2021-07-12 Impact factor: 4.379